HLA-DRB5 knockdown mitigated ITP by increasing peripheral PLT level, downregulating expressions of MHC-II and co-stimulatory molecules and inactivating CD8+ T cells. This evidence concerns the gene CD8A and autoimmune thrombocytopenic purpura.